Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1990 1
1993 1
1994 1
1995 1
1996 1
1999 1
2001 1
2002 5
2003 1
2004 1
2008 1
2010 2
2011 8
2012 4
2013 8
2014 12
2015 10
2016 7
2017 7
2018 10
2019 10
2020 13
2021 17
2022 6
2023 10
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures.
Pe M, Alanya A, Falk RS, Amdal CD, Bjordal K, Chang J, Cislo P, Coens C, Dirven L, Speck RM, Fitzgerald K, Galinsky J, Giesinger JM, Holzner B, Le Cessie S, O'Connor D, Oliver K, Pawar V, Quinten C, Schlichting M, Ren J, Roychoudhury S, Taphoorn MJB, Velikova G, Wintner LM, Griebsch I, Bottomley A; SISAQOL-IMI Consortium. Pe M, et al. Lancet Oncol. 2023 Jun;24(6):e270-e283. doi: 10.1016/S1470-2045(23)00157-2. Lancet Oncol. 2023. PMID: 37269858 Free article. Review.
The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors.
Tesileanu CMS, Michaleas S, Gonzalo Ruiz R, Mariz S, Fabriek BO, van Hennik PB, Dedorath J, Dekic B, Unkrig C, Brandt A, Koenig J, Enzmann H, Delgado J, Pignatti F. Tesileanu CMS, et al. Among authors: pignatti f. Oncologist. 2023 Jul 5;28(7):628-632. doi: 10.1093/oncolo/oyad119. Oncologist. 2023. PMID: 37141403 Free PMC article. Clinical Trial.
The value of anticancer drugs - a regulatory view.
Pignatti F, Wilking U, Postmus D, Wilking N, Delgado J, Bergh J. Pignatti F, et al. Nat Rev Clin Oncol. 2022 Mar;19(3):207-215. doi: 10.1038/s41571-021-00584-z. Epub 2021 Dec 6. Nat Rev Clin Oncol. 2022. PMID: 34873312 Review.
Ethical Aspects of Regulating Oncology Products.
Guizzaro L, Drosos S, Kihlbom U, Pignatti F. Guizzaro L, et al. Among authors: pignatti f. Recent Results Cancer Res. 2021;218:119-134. doi: 10.1007/978-3-030-63749-1_9. Recent Results Cancer Res. 2021. PMID: 34019166
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.
Taskén K, F Haj Mohammad S, Fagereng GL, Sørum Falk R, Helland Å, Barjesteh van Waalwijk van Doorn-Khosrovani S, Steen Carlsson K, Ryll B, Jalkanen K, Edsjö A, Russnes HG, Lassen U, Hallersjö Hult E, Lugowska I, Blay JY, Verlingue L, Abel E, Lowery MA, Krebs MG, Staal Rohrberg K, Ojamaa K, Oliveira J, Verheul HMW, Voest EE, Gelderblom H; PRIME-ROSE Consortium and the PCM4EU Consortium. Taskén K, et al. Acta Oncol. 2024 May 23;63:385-391. doi: 10.2340/1651-226X.2024.34791. Acta Oncol. 2024. PMID: 38779910 Free PMC article.
A Review of Causal Inference for External Comparator Arm Studies.
Rippin G, Ballarini N, Sanz H, Largent J, Quinten C, Pignatti F. Rippin G, et al. Among authors: pignatti f. Drug Saf. 2022 Aug;45(8):815-837. doi: 10.1007/s40264-022-01206-y. Epub 2022 Jul 27. Drug Saf. 2022. PMID: 35895225 Review.
Early market access of cancer drugs in the EU.
Martinalbo J, Bowen D, Camarero J, Chapelin M, Démolis P, Foggi P, Jonsson B, Llinares J, Moreau A, O'Connor D, Oliveira J, Vamvakas S, Pignatti F. Martinalbo J, et al. Among authors: pignatti f. Ann Oncol. 2016 Jan;27(1):96-105. doi: 10.1093/annonc/mdv506. Epub 2015 Oct 20. Ann Oncol. 2016. PMID: 26487583 Free article. Review.
Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth.
Eichler HG, Pignatti F, Schwarzer-Daum B, Hidalgo-Simon A, Eichler I, Arlett P, Humphreys A, Vamvakas S, Brun N, Rasi G. Eichler HG, et al. Among authors: pignatti f. Clin Pharmacol Ther. 2021 May;109(5):1212-1218. doi: 10.1002/cpt.2083. Epub 2020 Nov 12. Clin Pharmacol Ther. 2021. PMID: 33063841 Free PMC article. Review.
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.
Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG. Blumenthal GM, et al. Among authors: pignatti f. J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. J Thorac Oncol. 2018. PMID: 30268698 Free article. Review.
132 results